ArticleJournal of nanobiotechnology2026
Reprogramming microglia via ShK-modified extracellular vesicles promotes immunomodulation and functional recovery after spinal cord injury.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Microglia play a dual role in tissue repair and inflammatory responses following spinal cord injury (SCI), rendering the regulation of their immune activity a key therapeutic objective during disease progression. Single‑cell RNA sequencing revealed a significant upregulation of Kv1.3 expression in microglia following SCI, implicating this channel in the initiation of early neuroinflammation. To selectively target Kv1.3, engineered extracellular vesicles displaying ShK (ShK-EVs), a highly selective Kv1.3‑blocking peptide, were developed. These ShK‑EVs efficiently accumulated at the lesion site and were preferentially internalized by activated microglia. Integrated high‑throughput miRNA sequencing and proteomic profiling indicated that ShK‑EVs possess substantial neurorepair potential. Mechanistically, ShK‑EVs suppressed M1‑type microglial polarization and reduced the secretion of pro‑inflammatory cytokines by modulating the JAK/STAT signaling pathway. This modulation resulted in reduced tissue cavitation and neuronal apoptosis, enhanced neuronal survival and axonal regeneration, and ultimately led to a significant improvement in motor function in SCI mice. Taken together, these findings identify Kv1.3 as a key regulator of microglial activation after SCI and provide a novel, targeted therapeutic strategy using ShK‑EVs, offering new perspectives on immunomodulation of the injury microenvironment and functional neural recovery.
Indexed as
Identifiers
42881448What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.